共 48 条
[42]
Treatment of advanced HIV disease in antiretroviral-naive HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine
[J].
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV,
2011, 23 (11)
:1500-1504
[43]
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naı<spacing diaeresis>ve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study
[J].
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION,
2024, 57 (05)
:760-770
[45]
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naive patients
[J].
HIV RESEARCH & CLINICAL PRACTICE,
2021, 22 (05)
:128-139
[47]
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India
[J].
HIV MEDICINE,
2020, 21 (09)
:578-587
[48]
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
[J].
LANCET HIV,
2019, 6 (10)
:E655-E666